Journal article
Phenotypic consequences of slc25a40-abcb1 fusions beyond drug resistance in high-grade serous ovarian cancer
KI Pishas, KJ Cowley, A Pandey, T Hoang, JA Beach, J Luu, R Vary, LK Smith, CE Shembrey, N Rashoo, MO White, KJ Simpson, A Bild, JI Griffiths, D Cheasley, I Campbell, DDL Bowtell, EL Christie
Cancers | MDPI | Published : 2021
Abstract
Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) ultimately develop drug resistance within 1–2 years of treatment. We previously identified the most common mechanism of acquired resistance in HGSOC to date, transcriptional fusions involving the ATP-binding cassette (ABC) transporter ABCB1, which has well established roles in multidrug resistance. However, the underlying biology of fusion-positive cells, as well as how clonal interactions between fusion-negative and positive populations influences proliferative fitness and therapeutic response remains unknown. Using a panel of fusion-negative and positive HGSOC ..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This study was supported by grants from the National Health and Medical Research Council of Australia (NHMRC, APP1124309), Victorian Cancer Agency (ECSG15012), and US National Cancer Institute U54 program (U54CA209978). K.I. Pishas acknowledges financial support from the NHMRC CJ Martin Overseas Biomedical Fellowship (APP1111032) and a Therapeutic Innovation Australia Pipeline Accelerator Grant. David D.L Bowtell acknowledges financial support from the Cancer Systems Biology Center U54 grant (U54CA209978, NCI, NIH). L.K Smith acknowledges financial support from Cancer Council Victoria (APP1184894). E.L. Christie acknowledges financial support from NHMRC (APP1161198). J. Beach was supported by the American Australian Association Sir Keith Murdoch Fellowship. The Victorian Centre for Functional Genomics (K.J.S.) is funded by the Australian Cancer Research Foundation (ACRF), Phenomics Australia (PA) through funding from the Australian Government's National Collaborative Research Infrastructure Strategy (NCRIS) program, the Peter MacCallum Cancer Centre Foundation and the University of Melbourne Research Collaborative Infrastructure Program (MCRIP).